Arbutus Biopharma Corporation ABUS Gain (Loss), Foreign Currency Transaction, before Tax
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossBeforeTax.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's gain (loss), foreign currency transaction, before tax.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's gain (loss), foreign currency transaction, before tax?
- Arbutus Biopharma Corporation (ABUS) reported gain (loss), foreign currency transaction, before tax of -$11K in Q1 2026.
- How has Arbutus Biopharma Corporation's gain (loss), foreign currency transaction, before tax changed year-over-year?
- Arbutus Biopharma Corporation's gain (loss), foreign currency transaction, before tax decreased by 375.0% year-over-year, from $4K to -$11K.
- What is the long-term trend for Arbutus Biopharma Corporation's gain (loss), foreign currency transaction, before tax?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's gain (loss), foreign currency transaction, before tax has grown at a 29.4% compound annual growth rate (CAGR), from $5K to $14K.